Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RXDX-105 + Volasertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RXDX-105 | AC013773|CEP-32496|Agerafenib | ABL Inhibitor (pan) 9 ABL1 Inhibitor 8 BCR-ABL Inhibitor 32 BRAF Inhibitor 25 CRAF Inhibitor 12 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RET Inhibitor 53 VEGFR2 Inhibitor 37 | Agerafenib (RXDX-105) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199, PMID: 31695841). | |
Volasertib | BI 6727|BI6727|BI-6727 | PLK1 Inhibitor 18 | Volasertib (BI 6727) inhibits polo-like kinase I (PLK1), resulting in cell cycle arrest and apoptosis in tumor cells (PMID: 27330107, PMID: 30782614, PMID: 32728610). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|